Patent · US Active

Pulmonary delivery of mRNA to non-lung target cells

US11090264B2 · kind B2 · utility

2Cited by

67References

2Claims

0Family size

Assignees

TRANSLATE BIO, INC. · US
ethris GmbH · DE

Inventors

Michael Heartlein · Boxborough, US
Braydon Charles Guild · Concord, US
Frank DeRosa · Lexington, US
Carsten Rudolph · Krailling, DE
Christian Plank · Wien, AT

Key dates

Filing date	Jan 25, 2019
Grant date	Aug 17, 2021
Priority date	—
Expiry date	Jan 25, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/6018
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions comprising mRNA formulated for pulmonary administration and related method for delivery of the mRNA and/or encoded protein to a non-lung cell or tissue. The compositions and methods may be used to prevent or ameliorate the symptoms of diseases associated with the mRNA encoded protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.